Cover Image
市場調查報告書

EpiCast Report:腦膜炎性疾病的流行病學的預測

EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2025

出版商 GlobalData 商品編碼 270722
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:腦膜炎性疾病的流行病學的預測 EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2025
出版日期: 2016年06月01日 內容資訊: 英文 82 Pages
簡介

本報告提供全球主要國家的腦膜炎性疾病 (腦膜炎性腦膜炎等)的發病情形與今後預測相關分析,疾病的特徵,及目前罹患、普及情形,今後10年的發病數量的預測值等調查評估。

第1章 目錄

第2章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全球各國趨勢
    • 美國
    • EU主要5個國家
    • 日本、巴西
  • 預測手法
    • 利用之資訊來源
    • 預測的假設、手法
    • 未利用之資訊來源
  • 侵入性腦膜炎性疾病 (IMD)的流行病學的預測:今後11年份
    • IMD的發病者數總數
    • 發病率 (血清群B的情況)
    • 發病率 (血清群C的情況)
    • 發病率 (血清群Y的情況)
    • 發病率 (其他血清群的情況)
    • 血清群相關討論
    • 美國的大學1年級的情況
  • 討論
    • 流行病學的趨勢相關結論
    • 分析的限制
    • 分析的優勢

第3章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER118-16

Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis), an encapsulated gram-negative diplococcus that is a pathogen exclusive to humans. N. meningitidis is carried harmlessly in the nasopharynx of approximately 5?11% of adults and up to 25% of adolescents. Life-threatening disease occurs when the bacterium invades body tissue, which most commonly manifests as meningitis or septicemia. The disease is transmitted via respiratory droplets, through close or prolonged contact with an infected individual. N. meningitidis is classified into 13 distinct serogroups; however, almost all invasive disease in humans is a result of infection with one of 6 serogroups.

In the 8MM, GlobalData epidemiologists forecast that the laboratory-confirmed incident cases of IMD will decrease from 4,153 cases in 2015 to 3,169 cases in 2025 at an Annual Growth Rate (AGR) of negative 2.37%. Brazil had the highest number of laboratory-confirmed incident cases of IMD among the individual markets of the 8MM throughout the forecast period. The 5EU combined will account for 45.32% of laboratory-confirmed incident cases in 2015, and by 2025 this is forecast to increase to 59.58%. In the 8MM in 2015, 43.37% of the laboratory-confirmed incident cases of IMD are serogroup C disease, 36.46% are serogroup B disease, 5.25% are serogroup Y disease, and 14.98% are disease caused by other serogroups combined. GlobalData epidemiologists estimated that in the 8MM in 2015, 10.86% of laboratory-confirmed incident cases of IMD would occur in the population less than 1 year of age.

Scope

  • The Meningococcal disease (IMD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for IMD in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Brazil). For the US, 5EU (France, Germany, Italy, Spain, and UK), and Brazil, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of all IMD (all serogroups combined), segmented by sex and age (in age groups of <1 year and 1-4 years, then in 10 year age groups to =65 years), and laboratory-confirmed incident cases of serogroup B, serogroup C, serogroup Y, and all other IMD combined. For Japan, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of IMD segmented by sex and age (<1 year and =1 year); and a 10-year epidemiological forecast for laboratory-confirmed incident cases of specific serogroups. For the US, this report also provides a 10-year forecast of the number of first-year college students and the number of first-year college students living in campus accommodation.
  • The IMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The IMD EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global IMD market.
  • Quantify patient populations in the global IMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IMD therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Epidemiology

  • 2.1. Disease Background
  • 2.2. Risk Factors and morbidities
  • 2.3. Global Trends
    • 2.3.1. US
    • 2.3.2. 5EU
    • 2.3.3. Japan and Brazil
  • 2.4. Forecast Methodology
    • 2.4.1. Sources Used Tables
    • 2.4.2. Forecast Assumptions and Methods
    • 2.4.3. Sources Not Used
  • 2.5. Epidemiological Forecast for IMD (2015-2025)
    • 2.5.1. All IMD Combined
    • 2.5.2. Laboratory-Confirmed Incident Cases of Serogroup B IMD
    • 2.5.3. Laboratory-Confirmed Incident Cases of Serogroup C IMD
    • 2.5.4. Laboratory-Confirmed Incident Cases of Serogroup Y IMD
    • 2.5.5. Laboratory-Confirmed Incident Cases of Other Serogroup IMD
    • 2.5.6. Distribution of Serogroups
    • 2.5.7. US College Freshmen
  • 2.6. Discussion
    • 2.6.1. Epidemiological Forecast Insight
    • 2.6.2. Limitations of the Analysis
    • 2.6.3. Strengths of the Analysis

3. Appendix

  • 3.1. Bibliography
  • 3.2. About the Authors
    • 3.2.1. Epidemiologists
    • 3.2.2. Reviewers
    • 3.2.3. Global Director of Therapy Analysis and Epidemiology
    • 3.2.4. Global Head of Healthcare
  • 3.3. About GlobalData
  • 3.4. About EpiCast
  • 3.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for IMD
  • Table 2: 8MM, Sources of Laboratory-Confirmed IMD Incidence
  • Table 3: 8MM, Sources of Laboratory-Confirmed Serogroup B IMD Incidence
  • Table 4: 8MM, Sources of Laboratory-Confirmed Serogroup C IMD Incidence
  • Table 5: 8MM, Sources of Laboratory-Confirmed Serogroup Y IMD Incidence
  • Table 6: 8MM, Sources of Laboratory-Confirmed Other Serogroup IMD Incidence (Includes Serogroups A, W-135, X, and All Others)
  • Table 7: 5EU, Japan, and Brazil Sources of Laboratory-Confirmed Serogroup W-135 IMD Incidence
  • Table 8: Germany, Italy, and Brazil, Sources of Laboratory-Confirmed Serogroup A IMD Incidence
  • Table 9: College Freshmen Residing in Campus Accommodation
  • Table 10: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Table 11: 8MM and Japan, Age-specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015
  • Table 12: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015
  • Table 13: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N (Row %), 2015
  • Table 14: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Table 15: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Table 16: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Table 17: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Table 18: College Freshmen in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025

List of Figures

  • Figure 1: Laboratory-Confirmed Incidence of IMD in the EU, All Ages, Both Sexes, 2000-2014
  • Figure 2: 8MM, Laboratory-Confirmed Incident Cases of all IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Figure 3: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, 2015
  • Figure 4: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, 2015
  • Figure 5: 8MM, Age-Standardized Laboratory-Confirmed Incidence (Cases per 100,000 Population) of IMD, All Ages, by Sex, 2015
  • Figure 6: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
  • Figure 7: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Figure 8: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Figure 9: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
  • Figure 10: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2015
  • Figure 11: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2025
  • Figure 12: College Freshmen Living in Campus Accommodation in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025
Back to Top